COVID-19 Impact on Global Cancer Immunotherapies Market Insights, Forecast to 2026
Cancer Immunotherapies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Immunotherapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cancer Immunotherapies market is segmented into
The Cancer Immunotherapies market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cancer Immunotherapies market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Immunotherapies Market Share Analysis
Cancer Immunotherapies market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Immunotherapies business, the date to enter into the Cancer Immunotherapies market, Cancer Immunotherapies product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Cancer Immunotherapies market is segmented into
- Monoclonal Antibodies (MABs)
- Cancer Vaccines
- Immunomodulators
- Adoptive Cell transfer
- Checkpoint Inhibitors
- Breast Cancer
- Leukemia
- Lymphoma
- Melanoma
- Colorectal Cancer
- Non-Small Cell Lung Cancer
The Cancer Immunotherapies market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cancer Immunotherapies market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Immunotherapies Market Share Analysis
Cancer Immunotherapies market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Immunotherapies business, the date to enter into the Cancer Immunotherapies market, Cancer Immunotherapies product introduction, recent developments, etc.
The major vendors covered:
- Amgen
- AstraZeneca
- Roche
- Bristol-Myers Squibb
- Bayer
- Merck
- ARMO BioSciences (Eli Lilly)
- Novartis
- Pfizer
- Johnson & Johnson
- AbbVie
- Gilead Sciences
1 STUDY COVERAGE
1.1 Cancer Immunotherapies Product Introduction
1.2 Market Segments
1.3 Key Cancer Immunotherapies Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cancer Immunotherapies Market Size Growth Rate by Type
1.4.2 Monoclonal Antibodies (MABs)
1.4.3 Cancer Vaccines
1.4.4 Immunomodulators
1.4.5 Adoptive Cell transfer
1.4.6 Checkpoint Inhibitors
1.5 Market by Application
1.5.1 Global Cancer Immunotherapies Market Size Growth Rate by Application
1.5.2 Breast Cancer
1.5.3 Leukemia
1.5.4 Lymphoma
1.5.5 Melanoma
1.5.6 Colorectal Cancer
1.5.7 Non-Small Cell Lung Cancer
1.6 Coronavirus Disease 2019 (Covid-19): Cancer Immunotherapies Industry Impact
1.6.1 How the Covid-19 is Affecting the Cancer Immunotherapies Industry
1.6.1.1 Cancer Immunotherapies Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Cancer Immunotherapies Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Cancer Immunotherapies Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Cancer Immunotherapies Market Size Estimates and Forecasts
2.1.1 Global Cancer Immunotherapies Revenue 2015-2026
2.1.2 Global Cancer Immunotherapies Sales 2015-2026
2.2 Cancer Immunotherapies Market Size by Region: 2020 Versus 2026
2.2.1 Global Cancer Immunotherapies Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cancer Immunotherapies Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL CANCER IMMUNOTHERAPIES COMPETITOR LANDSCAPE BY PLAYERS
3.1 Cancer Immunotherapies Sales by Manufacturers
3.1.1 Cancer Immunotherapies Sales by Manufacturers (2015-2020)
3.1.2 Cancer Immunotherapies Sales Market Share by Manufacturers (2015-2020)
3.2 Cancer Immunotherapies Revenue by Manufacturers
3.2.1 Cancer Immunotherapies Revenue by Manufacturers (2015-2020)
3.2.2 Cancer Immunotherapies Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cancer Immunotherapies Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cancer Immunotherapies Revenue in 2019
3.2.5 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cancer Immunotherapies Price by Manufacturers
3.4 Cancer Immunotherapies Manufacturing Base Distribution, Product Types
3.4.1 Cancer Immunotherapies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Immunotherapies Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Immunotherapies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Cancer Immunotherapies Market Size by Type (2015-2020)
4.1.1 Global Cancer Immunotherapies Sales by Type (2015-2020)
4.1.2 Global Cancer Immunotherapies Revenue by Type (2015-2020)
4.1.3 Cancer Immunotherapies Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cancer Immunotherapies Market Size Forecast by Type (2021-2026)
4.2.1 Global Cancer Immunotherapies Sales Forecast by Type (2021-2026)
4.2.2 Global Cancer Immunotherapies Revenue Forecast by Type (2021-2026)
4.2.3 Cancer Immunotherapies Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cancer Immunotherapies Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Cancer Immunotherapies Market Size by Application (2015-2020)
5.1.1 Global Cancer Immunotherapies Sales by Application (2015-2020)
5.1.2 Global Cancer Immunotherapies Revenue by Application (2015-2020)
5.1.3 Cancer Immunotherapies Price by Application (2015-2020)
5.2 Cancer Immunotherapies Market Size Forecast by Application (2021-2026)
5.2.1 Global Cancer Immunotherapies Sales Forecast by Application (2021-2026)
5.2.2 Global Cancer Immunotherapies Revenue Forecast by Application (2021-2026)
5.2.3 Global Cancer Immunotherapies Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Cancer Immunotherapies by Country
6.1.1 North America Cancer Immunotherapies Sales by Country
6.1.2 North America Cancer Immunotherapies Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cancer Immunotherapies Market Facts & Figures by Type
6.3 North America Cancer Immunotherapies Market Facts & Figures by Application
7 EUROPE
7.1 Europe Cancer Immunotherapies by Country
7.1.1 Europe Cancer Immunotherapies Sales by Country
7.1.2 Europe Cancer Immunotherapies Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Immunotherapies Market Facts & Figures by Type
7.3 Europe Cancer Immunotherapies Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Cancer Immunotherapies by Region
8.1.1 Asia Pacific Cancer Immunotherapies Sales by Region
8.1.2 Asia Pacific Cancer Immunotherapies Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Type
8.3 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Cancer Immunotherapies by Country
9.1.1 Latin America Cancer Immunotherapies Sales by Country
9.1.2 Latin America Cancer Immunotherapies Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cancer Immunotherapies Market Facts & Figures by Type
9.3 Central & South America Cancer Immunotherapies Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Cancer Immunotherapies by Country
10.1.1 Middle East and Africa Cancer Immunotherapies Sales by Country
10.1.2 Middle East and Africa Cancer Immunotherapies Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Type
10.3 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description, Business Overview and Total Revenue
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Cancer Immunotherapies Products Offered
11.1.5 Amgen Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Description, Business Overview and Total Revenue
11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Cancer Immunotherapies Products Offered
11.2.5 AstraZeneca Recent Development
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Description, Business Overview and Total Revenue
11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Roche Cancer Immunotherapies Products Offered
11.3.5 Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Corporation Information
11.4.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
11.4.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Bayer
11.5.1 Bayer Corporation Information
11.5.2 Bayer Description, Business Overview and Total Revenue
11.5.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bayer Cancer Immunotherapies Products Offered
11.5.5 Bayer Recent Development
11.6 Merck
11.6.1 Merck Corporation Information
11.6.2 Merck Description, Business Overview and Total Revenue
11.6.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Merck Cancer Immunotherapies Products Offered
11.6.5 Merck Recent Development
11.7 ARMO BioSciences (Eli Lilly)
11.7.1 ARMO BioSciences (Eli Lilly) Corporation Information
11.7.2 ARMO BioSciences (Eli Lilly) Description, Business Overview and Total Revenue
11.7.3 ARMO BioSciences (Eli Lilly) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered
11.7.5 ARMO BioSciences (Eli Lilly) Recent Development
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Description, Business Overview and Total Revenue
11.8.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Novartis Cancer Immunotherapies Products Offered
11.8.5 Novartis Recent Development
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Description, Business Overview and Total Revenue
11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Pfizer Cancer Immunotherapies Products Offered
11.9.5 Pfizer Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Corporation Information
11.10.2 Johnson & Johnson Description, Business Overview and Total Revenue
11.10.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered
11.10.5 Johnson & Johnson Recent Development
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description, Business Overview and Total Revenue
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Cancer Immunotherapies Products Offered
11.1.5 Amgen Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Corporation Information
11.12.2 Gilead Sciences Description, Business Overview and Total Revenue
11.12.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Gilead Sciences Products Offered
11.12.5 Gilead Sciences Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Cancer Immunotherapies Market Estimates and Projections by Region
12.1.1 Global Cancer Immunotherapies Sales Forecast by Regions 2021-2026
12.1.2 Global Cancer Immunotherapies Revenue Forecast by Regions 2021-2026
12.2 North America Cancer Immunotherapies Market Size Forecast (2021-2026)
12.2.1 North America: Cancer Immunotherapies Sales Forecast (2021-2026)
12.2.2 North America: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.2.3 North America: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
12.3 Europe Cancer Immunotherapies Market Size Forecast (2021-2026)
12.3.1 Europe: Cancer Immunotherapies Sales Forecast (2021-2026)
12.3.2 Europe: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.3.3 Europe: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cancer Immunotherapies Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cancer Immunotherapies Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cancer Immunotherapies Market Size Forecast by Region (2021-2026)
12.5 Latin America Cancer Immunotherapies Market Size Forecast (2021-2026)
12.5.1 Latin America: Cancer Immunotherapies Sales Forecast (2021-2026)
12.5.2 Latin America: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.5.3 Latin America: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cancer Immunotherapies Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cancer Immunotherapies Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cancer Immunotherapies Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Cancer Immunotherapies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Cancer Immunotherapies Product Introduction
1.2 Market Segments
1.3 Key Cancer Immunotherapies Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cancer Immunotherapies Market Size Growth Rate by Type
1.4.2 Monoclonal Antibodies (MABs)
1.4.3 Cancer Vaccines
1.4.4 Immunomodulators
1.4.5 Adoptive Cell transfer
1.4.6 Checkpoint Inhibitors
1.5 Market by Application
1.5.1 Global Cancer Immunotherapies Market Size Growth Rate by Application
1.5.2 Breast Cancer
1.5.3 Leukemia
1.5.4 Lymphoma
1.5.5 Melanoma
1.5.6 Colorectal Cancer
1.5.7 Non-Small Cell Lung Cancer
1.6 Coronavirus Disease 2019 (Covid-19): Cancer Immunotherapies Industry Impact
1.6.1 How the Covid-19 is Affecting the Cancer Immunotherapies Industry
1.6.1.1 Cancer Immunotherapies Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Cancer Immunotherapies Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Cancer Immunotherapies Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Cancer Immunotherapies Market Size Estimates and Forecasts
2.1.1 Global Cancer Immunotherapies Revenue 2015-2026
2.1.2 Global Cancer Immunotherapies Sales 2015-2026
2.2 Cancer Immunotherapies Market Size by Region: 2020 Versus 2026
2.2.1 Global Cancer Immunotherapies Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cancer Immunotherapies Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL CANCER IMMUNOTHERAPIES COMPETITOR LANDSCAPE BY PLAYERS
3.1 Cancer Immunotherapies Sales by Manufacturers
3.1.1 Cancer Immunotherapies Sales by Manufacturers (2015-2020)
3.1.2 Cancer Immunotherapies Sales Market Share by Manufacturers (2015-2020)
3.2 Cancer Immunotherapies Revenue by Manufacturers
3.2.1 Cancer Immunotherapies Revenue by Manufacturers (2015-2020)
3.2.2 Cancer Immunotherapies Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cancer Immunotherapies Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cancer Immunotherapies Revenue in 2019
3.2.5 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cancer Immunotherapies Price by Manufacturers
3.4 Cancer Immunotherapies Manufacturing Base Distribution, Product Types
3.4.1 Cancer Immunotherapies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Immunotherapies Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Immunotherapies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Cancer Immunotherapies Market Size by Type (2015-2020)
4.1.1 Global Cancer Immunotherapies Sales by Type (2015-2020)
4.1.2 Global Cancer Immunotherapies Revenue by Type (2015-2020)
4.1.3 Cancer Immunotherapies Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cancer Immunotherapies Market Size Forecast by Type (2021-2026)
4.2.1 Global Cancer Immunotherapies Sales Forecast by Type (2021-2026)
4.2.2 Global Cancer Immunotherapies Revenue Forecast by Type (2021-2026)
4.2.3 Cancer Immunotherapies Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cancer Immunotherapies Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Cancer Immunotherapies Market Size by Application (2015-2020)
5.1.1 Global Cancer Immunotherapies Sales by Application (2015-2020)
5.1.2 Global Cancer Immunotherapies Revenue by Application (2015-2020)
5.1.3 Cancer Immunotherapies Price by Application (2015-2020)
5.2 Cancer Immunotherapies Market Size Forecast by Application (2021-2026)
5.2.1 Global Cancer Immunotherapies Sales Forecast by Application (2021-2026)
5.2.2 Global Cancer Immunotherapies Revenue Forecast by Application (2021-2026)
5.2.3 Global Cancer Immunotherapies Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Cancer Immunotherapies by Country
6.1.1 North America Cancer Immunotherapies Sales by Country
6.1.2 North America Cancer Immunotherapies Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cancer Immunotherapies Market Facts & Figures by Type
6.3 North America Cancer Immunotherapies Market Facts & Figures by Application
7 EUROPE
7.1 Europe Cancer Immunotherapies by Country
7.1.1 Europe Cancer Immunotherapies Sales by Country
7.1.2 Europe Cancer Immunotherapies Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Immunotherapies Market Facts & Figures by Type
7.3 Europe Cancer Immunotherapies Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Cancer Immunotherapies by Region
8.1.1 Asia Pacific Cancer Immunotherapies Sales by Region
8.1.2 Asia Pacific Cancer Immunotherapies Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Type
8.3 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Cancer Immunotherapies by Country
9.1.1 Latin America Cancer Immunotherapies Sales by Country
9.1.2 Latin America Cancer Immunotherapies Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cancer Immunotherapies Market Facts & Figures by Type
9.3 Central & South America Cancer Immunotherapies Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Cancer Immunotherapies by Country
10.1.1 Middle East and Africa Cancer Immunotherapies Sales by Country
10.1.2 Middle East and Africa Cancer Immunotherapies Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Type
10.3 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description, Business Overview and Total Revenue
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Cancer Immunotherapies Products Offered
11.1.5 Amgen Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Description, Business Overview and Total Revenue
11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Cancer Immunotherapies Products Offered
11.2.5 AstraZeneca Recent Development
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Description, Business Overview and Total Revenue
11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Roche Cancer Immunotherapies Products Offered
11.3.5 Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Corporation Information
11.4.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
11.4.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Bayer
11.5.1 Bayer Corporation Information
11.5.2 Bayer Description, Business Overview and Total Revenue
11.5.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bayer Cancer Immunotherapies Products Offered
11.5.5 Bayer Recent Development
11.6 Merck
11.6.1 Merck Corporation Information
11.6.2 Merck Description, Business Overview and Total Revenue
11.6.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Merck Cancer Immunotherapies Products Offered
11.6.5 Merck Recent Development
11.7 ARMO BioSciences (Eli Lilly)
11.7.1 ARMO BioSciences (Eli Lilly) Corporation Information
11.7.2 ARMO BioSciences (Eli Lilly) Description, Business Overview and Total Revenue
11.7.3 ARMO BioSciences (Eli Lilly) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered
11.7.5 ARMO BioSciences (Eli Lilly) Recent Development
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Description, Business Overview and Total Revenue
11.8.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Novartis Cancer Immunotherapies Products Offered
11.8.5 Novartis Recent Development
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Description, Business Overview and Total Revenue
11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Pfizer Cancer Immunotherapies Products Offered
11.9.5 Pfizer Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Corporation Information
11.10.2 Johnson & Johnson Description, Business Overview and Total Revenue
11.10.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered
11.10.5 Johnson & Johnson Recent Development
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description, Business Overview and Total Revenue
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Cancer Immunotherapies Products Offered
11.1.5 Amgen Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Corporation Information
11.12.2 Gilead Sciences Description, Business Overview and Total Revenue
11.12.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Gilead Sciences Products Offered
11.12.5 Gilead Sciences Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Cancer Immunotherapies Market Estimates and Projections by Region
12.1.1 Global Cancer Immunotherapies Sales Forecast by Regions 2021-2026
12.1.2 Global Cancer Immunotherapies Revenue Forecast by Regions 2021-2026
12.2 North America Cancer Immunotherapies Market Size Forecast (2021-2026)
12.2.1 North America: Cancer Immunotherapies Sales Forecast (2021-2026)
12.2.2 North America: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.2.3 North America: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
12.3 Europe Cancer Immunotherapies Market Size Forecast (2021-2026)
12.3.1 Europe: Cancer Immunotherapies Sales Forecast (2021-2026)
12.3.2 Europe: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.3.3 Europe: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cancer Immunotherapies Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cancer Immunotherapies Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cancer Immunotherapies Market Size Forecast by Region (2021-2026)
12.5 Latin America Cancer Immunotherapies Market Size Forecast (2021-2026)
12.5.1 Latin America: Cancer Immunotherapies Sales Forecast (2021-2026)
12.5.2 Latin America: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.5.3 Latin America: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cancer Immunotherapies Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cancer Immunotherapies Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cancer Immunotherapies Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cancer Immunotherapies Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cancer Immunotherapies Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Cancer Immunotherapies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Cancer Immunotherapies Market Segments
Table 2. Ranking of Global Top Cancer Immunotherapies Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cancer Immunotherapies Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Monoclonal Antibodies (MABs)
Table 5. Major Manufacturers of Cancer Vaccines
Table 6. Major Manufacturers of Immunomodulators
Table 7. Major Manufacturers of Adoptive Cell transfer
Table 8. Major Manufacturers of Checkpoint Inhibitors
Table 9. COVID-19 Impact Global Market: (Four Cancer Immunotherapies Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Cancer Immunotherapies Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Cancer Immunotherapies Players to Combat Covid-19 Impact
Table 14. Global Cancer Immunotherapies Market Size Growth Rate by Application 2020-2026 (K Units)
Table 15. Global Cancer Immunotherapies Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Cancer Immunotherapies Sales by Regions 2015-2020 (K Units)
Table 17. Global Cancer Immunotherapies Sales Market Share by Regions (2015-2020)
Table 18. Global Cancer Immunotherapies Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Cancer Immunotherapies Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Cancer Immunotherapies Sales Share by Manufacturers (2015-2020)
Table 21. Global Cancer Immunotherapies Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Immunotherapies as of 2019)
Table 23. Cancer Immunotherapies Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Cancer Immunotherapies Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Cancer Immunotherapies Price (2015-2020) (USD/Unit)
Table 26. Cancer Immunotherapies Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Cancer Immunotherapies Product Type
Table 28. Date of International Manufacturers Enter into Cancer Immunotherapies Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 31. Global Cancer Immunotherapies Sales Share by Type (2015-2020)
Table 32. Global Cancer Immunotherapies Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Cancer Immunotherapies Revenue Share by Type (2015-2020)
Table 34. Cancer Immunotherapies Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 36. Global Cancer Immunotherapies Sales Share by Application (2015-2020)
Table 37. North America Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 38. North America Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 39. North America Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 41. North America Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 42. North America Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 43. North America Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 44. North America Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 45. Europe Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 46. Europe Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 47. Europe Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 49. Europe Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 50. Europe Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 51. Europe Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 52. Europe Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Cancer Immunotherapies Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Cancer Immunotherapies Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Cancer Immunotherapies Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Cancer Immunotherapies Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 60. Asia Pacific Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 61. Latin America Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 62. Latin America Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 65. Latin America Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 66. Latin America Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 67. Latin America Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 68. Latin America Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 76. Middle East and Africa Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 77. Amgen Corporation Information
Table 78. Amgen Description and Major Businesses
Table 79. Amgen Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Amgen Product
Table 81. Amgen Recent Development
Table 82. AstraZeneca Corporation Information
Table 83. AstraZeneca Description and Major Businesses
Table 84. AstraZeneca Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. AstraZeneca Product
Table 86. AstraZeneca Recent Development
Table 87. Roche Corporation Information
Table 88. Roche Description and Major Businesses
Table 89. Roche Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Roche Product
Table 91. Roche Recent Development
Table 92. Bristol-Myers Squibb Corporation Information
Table 93. Bristol-Myers Squibb Description and Major Businesses
Table 94. Bristol-Myers Squibb Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Bristol-Myers Squibb Product
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Bayer Corporation Information
Table 98. Bayer Description and Major Businesses
Table 99. Bayer Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Bayer Product
Table 101. Bayer Recent Development
Table 102. Merck Corporation Information
Table 103. Merck Description and Major Businesses
Table 104. Merck Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Merck Product
Table 106. Merck Recent Development
Table 107. ARMO BioSciences (Eli Lilly) Corporation Information
Table 108. ARMO BioSciences (Eli Lilly) Description and Major Businesses
Table 109. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. ARMO BioSciences (Eli Lilly) Product
Table 111. ARMO BioSciences (Eli Lilly) Recent Development
Table 112. Novartis Corporation Information
Table 113. Novartis Description and Major Businesses
Table 114. Novartis Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Novartis Product
Table 116. Novartis Recent Development
Table 117. Pfizer Corporation Information
Table 118. Pfizer Description and Major Businesses
Table 119. Pfizer Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Pfizer Product
Table 121. Pfizer Recent Development
Table 122. Johnson & Johnson Corporation Information
Table 123. Johnson & Johnson Description and Major Businesses
Table 124. Johnson & Johnson Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Johnson & Johnson Product
Table 126. Johnson & Johnson Recent Development
Table 127. AbbVie Corporation Information
Table 128. AbbVie Description and Major Businesses
Table 129. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 130. AbbVie Product
Table 131. AbbVie Recent Development
Table 132. Gilead Sciences Corporation Information
Table 133. Gilead Sciences Description and Major Businesses
Table 134. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 135. Gilead Sciences Product
Table 136. Gilead Sciences Recent Development
Table 137. Global Cancer Immunotherapies Sales Forecast by Regions (2021-2026) (K Units)
Table 138. Global Cancer Immunotherapies Sales Market Share Forecast by Regions (2021-2026)
Table 139. Global Cancer Immunotherapies Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 140. Global Cancer Immunotherapies Revenue Market Share Forecast by Regions (2021-2026)
Table 141. North America: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 142. North America: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Europe: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 144. Europe: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 145. Asia Pacific: Cancer Immunotherapies Sales Forecast by Region (2021-2026) (K Units)
Table 146. Asia Pacific: Cancer Immunotherapies Revenue Forecast by Region (2021-2026) (US$ Million)
Table 147. Latin America: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 148. Latin America: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Middle East and Africa: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 150. Middle East and Africa: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 151. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 152. Key Challenges
Table 153. Market Risks
Table 154. Main Points Interviewed from Key Cancer Immunotherapies Players
Table 155. Cancer Immunotherapies Customers List
Table 156. Cancer Immunotherapies Distributors List
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
Table 1. Cancer Immunotherapies Market Segments
Table 2. Ranking of Global Top Cancer Immunotherapies Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cancer Immunotherapies Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Monoclonal Antibodies (MABs)
Table 5. Major Manufacturers of Cancer Vaccines
Table 6. Major Manufacturers of Immunomodulators
Table 7. Major Manufacturers of Adoptive Cell transfer
Table 8. Major Manufacturers of Checkpoint Inhibitors
Table 9. COVID-19 Impact Global Market: (Four Cancer Immunotherapies Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Cancer Immunotherapies Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Cancer Immunotherapies Players to Combat Covid-19 Impact
Table 14. Global Cancer Immunotherapies Market Size Growth Rate by Application 2020-2026 (K Units)
Table 15. Global Cancer Immunotherapies Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Cancer Immunotherapies Sales by Regions 2015-2020 (K Units)
Table 17. Global Cancer Immunotherapies Sales Market Share by Regions (2015-2020)
Table 18. Global Cancer Immunotherapies Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Cancer Immunotherapies Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Cancer Immunotherapies Sales Share by Manufacturers (2015-2020)
Table 21. Global Cancer Immunotherapies Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Immunotherapies as of 2019)
Table 23. Cancer Immunotherapies Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Cancer Immunotherapies Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Cancer Immunotherapies Price (2015-2020) (USD/Unit)
Table 26. Cancer Immunotherapies Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Cancer Immunotherapies Product Type
Table 28. Date of International Manufacturers Enter into Cancer Immunotherapies Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 31. Global Cancer Immunotherapies Sales Share by Type (2015-2020)
Table 32. Global Cancer Immunotherapies Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Cancer Immunotherapies Revenue Share by Type (2015-2020)
Table 34. Cancer Immunotherapies Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 36. Global Cancer Immunotherapies Sales Share by Application (2015-2020)
Table 37. North America Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 38. North America Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 39. North America Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 41. North America Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 42. North America Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 43. North America Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 44. North America Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 45. Europe Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 46. Europe Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 47. Europe Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 49. Europe Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 50. Europe Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 51. Europe Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 52. Europe Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Cancer Immunotherapies Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Cancer Immunotherapies Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Cancer Immunotherapies Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Cancer Immunotherapies Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 60. Asia Pacific Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 61. Latin America Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 62. Latin America Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 65. Latin America Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 66. Latin America Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 67. Latin America Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 68. Latin America Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Cancer Immunotherapies Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Cancer Immunotherapies Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Cancer Immunotherapies Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Cancer Immunotherapies Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Cancer Immunotherapies Sales by Application (2015-2020) (K Units)
Table 76. Middle East and Africa Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Table 77. Amgen Corporation Information
Table 78. Amgen Description and Major Businesses
Table 79. Amgen Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Amgen Product
Table 81. Amgen Recent Development
Table 82. AstraZeneca Corporation Information
Table 83. AstraZeneca Description and Major Businesses
Table 84. AstraZeneca Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. AstraZeneca Product
Table 86. AstraZeneca Recent Development
Table 87. Roche Corporation Information
Table 88. Roche Description and Major Businesses
Table 89. Roche Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Roche Product
Table 91. Roche Recent Development
Table 92. Bristol-Myers Squibb Corporation Information
Table 93. Bristol-Myers Squibb Description and Major Businesses
Table 94. Bristol-Myers Squibb Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Bristol-Myers Squibb Product
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Bayer Corporation Information
Table 98. Bayer Description and Major Businesses
Table 99. Bayer Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Bayer Product
Table 101. Bayer Recent Development
Table 102. Merck Corporation Information
Table 103. Merck Description and Major Businesses
Table 104. Merck Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Merck Product
Table 106. Merck Recent Development
Table 107. ARMO BioSciences (Eli Lilly) Corporation Information
Table 108. ARMO BioSciences (Eli Lilly) Description and Major Businesses
Table 109. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. ARMO BioSciences (Eli Lilly) Product
Table 111. ARMO BioSciences (Eli Lilly) Recent Development
Table 112. Novartis Corporation Information
Table 113. Novartis Description and Major Businesses
Table 114. Novartis Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Novartis Product
Table 116. Novartis Recent Development
Table 117. Pfizer Corporation Information
Table 118. Pfizer Description and Major Businesses
Table 119. Pfizer Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Pfizer Product
Table 121. Pfizer Recent Development
Table 122. Johnson & Johnson Corporation Information
Table 123. Johnson & Johnson Description and Major Businesses
Table 124. Johnson & Johnson Cancer Immunotherapies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Johnson & Johnson Product
Table 126. Johnson & Johnson Recent Development
Table 127. AbbVie Corporation Information
Table 128. AbbVie Description and Major Businesses
Table 129. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 130. AbbVie Product
Table 131. AbbVie Recent Development
Table 132. Gilead Sciences Corporation Information
Table 133. Gilead Sciences Description and Major Businesses
Table 134. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 135. Gilead Sciences Product
Table 136. Gilead Sciences Recent Development
Table 137. Global Cancer Immunotherapies Sales Forecast by Regions (2021-2026) (K Units)
Table 138. Global Cancer Immunotherapies Sales Market Share Forecast by Regions (2021-2026)
Table 139. Global Cancer Immunotherapies Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 140. Global Cancer Immunotherapies Revenue Market Share Forecast by Regions (2021-2026)
Table 141. North America: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 142. North America: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Europe: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 144. Europe: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 145. Asia Pacific: Cancer Immunotherapies Sales Forecast by Region (2021-2026) (K Units)
Table 146. Asia Pacific: Cancer Immunotherapies Revenue Forecast by Region (2021-2026) (US$ Million)
Table 147. Latin America: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 148. Latin America: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Middle East and Africa: Cancer Immunotherapies Sales Forecast by Country (2021-2026) (K Units)
Table 150. Middle East and Africa: Cancer Immunotherapies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 151. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 152. Key Challenges
Table 153. Market Risks
Table 154. Main Points Interviewed from Key Cancer Immunotherapies Players
Table 155. Cancer Immunotherapies Customers List
Table 156. Cancer Immunotherapies Distributors List
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Cancer Immunotherapies Product Picture
Figure 2. Global Cancer Immunotherapies Sales Market Share by Type in 2020 & 2026
Figure 3. Monoclonal Antibodies (MABs) Product Picture
Figure 4. Cancer Vaccines Product Picture
Figure 5. Immunomodulators Product Picture
Figure 6. Adoptive Cell transfer Product Picture
Figure 7. Checkpoint Inhibitors Product Picture
Figure 8. Global Cancer Immunotherapies Sales Market Share by Application in 2020 & 2026
Figure 9. Breast Cancer
Figure 10. Leukemia
Figure 11. Lymphoma
Figure 12. Melanoma
Figure 13. Colorectal Cancer
Figure 14. Non-Small Cell Lung Cancer
Figure 15. Cancer Immunotherapies Report Years Considered
Figure 16. Global Cancer Immunotherapies Market Size 2015-2026 (US$ Million)
Figure 17. Global Cancer Immunotherapies Sales 2015-2026 (K Units)
Figure 18. Global Cancer Immunotherapies Market Size Market Share by Region: 2020 Versus 2026
Figure 19. Global Cancer Immunotherapies Sales Market Share by Region (2015-2020)
Figure 20. Global Cancer Immunotherapies Sales Market Share by Region in 2019
Figure 21. Global Cancer Immunotherapies Revenue Market Share by Region (2015-2020)
Figure 22. Global Cancer Immunotherapies Revenue Market Share by Region in 2019
Figure 23. Global Cancer Immunotherapies Sales Share by Manufacturer in 2019
Figure 24. The Top 10 and 5 Players Market Share by Cancer Immunotherapies Revenue in 2019
Figure 25. Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 26. Global Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Figure 27. Global Cancer Immunotherapies Sales Market Share by Type in 2019
Figure 28. Global Cancer Immunotherapies Revenue Market Share by Type (2015-2020)
Figure 29. Global Cancer Immunotherapies Revenue Market Share by Type in 2019
Figure 30. Global Cancer Immunotherapies Market Share by Price Range (2015-2020)
Figure 31. Global Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Figure 32. Global Cancer Immunotherapies Sales Market Share by Application in 2019
Figure 33. Global Cancer Immunotherapies Revenue Market Share by Application (2015-2020)
Figure 34. Global Cancer Immunotherapies Revenue Market Share by Application in 2019
Figure 35. North America Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 36. North America Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 37. North America Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 38. North America Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 39. U.S. Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 40. U.S. Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Canada Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 42. Canada Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. North America Cancer Immunotherapies Market Share by Type in 2019
Figure 44. North America Cancer Immunotherapies Market Share by Application in 2019
Figure 45. Europe Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 46. Europe Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 47. Europe Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 48. Europe Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 49. Germany Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 50. Germany Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. France Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 52. France Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. U.K. Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 54. U.K. Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Italy Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 56. Italy Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Russia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 58. Russia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Europe Cancer Immunotherapies Market Share by Type in 2019
Figure 60. Europe Cancer Immunotherapies Market Share by Application in 2019
Figure 61. Asia Pacific Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 62. Asia Pacific Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 63. Asia Pacific Cancer Immunotherapies Sales Market Share by Region in 2019
Figure 64. Asia Pacific Cancer Immunotherapies Revenue Market Share by Region in 2019
Figure 65. China Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 66. China Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Japan Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 68. Japan Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. South Korea Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 70. South Korea Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. India Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 72. India Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Australia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 74. Australia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Taiwan Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 76. Taiwan Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Indonesia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 78. Indonesia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Thailand Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 80. Thailand Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Malaysia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 82. Malaysia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Philippines Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 84. Philippines Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Vietnam Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 86. Vietnam Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Asia Pacific Cancer Immunotherapies Market Share by Type in 2019
Figure 88. Asia Pacific Cancer Immunotherapies Market Share by Application in 2019
Figure 89. Latin America Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 90. Latin America Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 91. Latin America Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 92. Latin America Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 93. Mexico Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 94. Mexico Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Brazil Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 96. Brazil Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Argentina Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 98. Argentina Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Latin America Cancer Immunotherapies Market Share by Type in 2019
Figure 100. Latin America Cancer Immunotherapies Market Share by Application in 2019
Figure 101. Middle East and Africa Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 102. Middle East and Africa Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 103. Middle East and Africa Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 104. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 105. Turkey Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 106. Turkey Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Saudi Arabia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 108. Saudi Arabia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. U.A.E Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 110. U.A.E Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. Middle East and Africa Cancer Immunotherapies Market Share by Type in 2019
Figure 112. Middle East and Africa Cancer Immunotherapies Market Share by Application in 2019
Figure 113. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. ARMO BioSciences (Eli Lilly) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 122. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 123. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 124. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 125. North America Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 126. North America Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Europe Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 128. Europe Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Asia Pacific Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 130. Asia Pacific Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 131. Latin America Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 132. Latin America Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 133. Middle East and Africa Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 134. Middle East and Africa Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 135. Porter's Five Forces Analysis
Figure 136. Channels of Distribution
Figure 137. Distributors Profiles
Figure 138. Bottom-up and Top-down Approaches for This Report
Figure 139. Data Triangulation
Figure 140. Key Executives Interviewed
Figure 1. Cancer Immunotherapies Product Picture
Figure 2. Global Cancer Immunotherapies Sales Market Share by Type in 2020 & 2026
Figure 3. Monoclonal Antibodies (MABs) Product Picture
Figure 4. Cancer Vaccines Product Picture
Figure 5. Immunomodulators Product Picture
Figure 6. Adoptive Cell transfer Product Picture
Figure 7. Checkpoint Inhibitors Product Picture
Figure 8. Global Cancer Immunotherapies Sales Market Share by Application in 2020 & 2026
Figure 9. Breast Cancer
Figure 10. Leukemia
Figure 11. Lymphoma
Figure 12. Melanoma
Figure 13. Colorectal Cancer
Figure 14. Non-Small Cell Lung Cancer
Figure 15. Cancer Immunotherapies Report Years Considered
Figure 16. Global Cancer Immunotherapies Market Size 2015-2026 (US$ Million)
Figure 17. Global Cancer Immunotherapies Sales 2015-2026 (K Units)
Figure 18. Global Cancer Immunotherapies Market Size Market Share by Region: 2020 Versus 2026
Figure 19. Global Cancer Immunotherapies Sales Market Share by Region (2015-2020)
Figure 20. Global Cancer Immunotherapies Sales Market Share by Region in 2019
Figure 21. Global Cancer Immunotherapies Revenue Market Share by Region (2015-2020)
Figure 22. Global Cancer Immunotherapies Revenue Market Share by Region in 2019
Figure 23. Global Cancer Immunotherapies Sales Share by Manufacturer in 2019
Figure 24. The Top 10 and 5 Players Market Share by Cancer Immunotherapies Revenue in 2019
Figure 25. Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 26. Global Cancer Immunotherapies Sales Market Share by Type (2015-2020)
Figure 27. Global Cancer Immunotherapies Sales Market Share by Type in 2019
Figure 28. Global Cancer Immunotherapies Revenue Market Share by Type (2015-2020)
Figure 29. Global Cancer Immunotherapies Revenue Market Share by Type in 2019
Figure 30. Global Cancer Immunotherapies Market Share by Price Range (2015-2020)
Figure 31. Global Cancer Immunotherapies Sales Market Share by Application (2015-2020)
Figure 32. Global Cancer Immunotherapies Sales Market Share by Application in 2019
Figure 33. Global Cancer Immunotherapies Revenue Market Share by Application (2015-2020)
Figure 34. Global Cancer Immunotherapies Revenue Market Share by Application in 2019
Figure 35. North America Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 36. North America Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 37. North America Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 38. North America Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 39. U.S. Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 40. U.S. Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Canada Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 42. Canada Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. North America Cancer Immunotherapies Market Share by Type in 2019
Figure 44. North America Cancer Immunotherapies Market Share by Application in 2019
Figure 45. Europe Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 46. Europe Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 47. Europe Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 48. Europe Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 49. Germany Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 50. Germany Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. France Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 52. France Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. U.K. Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 54. U.K. Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Italy Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 56. Italy Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Russia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 58. Russia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Europe Cancer Immunotherapies Market Share by Type in 2019
Figure 60. Europe Cancer Immunotherapies Market Share by Application in 2019
Figure 61. Asia Pacific Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 62. Asia Pacific Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 63. Asia Pacific Cancer Immunotherapies Sales Market Share by Region in 2019
Figure 64. Asia Pacific Cancer Immunotherapies Revenue Market Share by Region in 2019
Figure 65. China Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 66. China Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Japan Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 68. Japan Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. South Korea Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 70. South Korea Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. India Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 72. India Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Australia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 74. Australia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Taiwan Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 76. Taiwan Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Indonesia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 78. Indonesia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Thailand Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 80. Thailand Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Malaysia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 82. Malaysia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Philippines Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 84. Philippines Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Vietnam Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 86. Vietnam Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Asia Pacific Cancer Immunotherapies Market Share by Type in 2019
Figure 88. Asia Pacific Cancer Immunotherapies Market Share by Application in 2019
Figure 89. Latin America Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 90. Latin America Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 91. Latin America Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 92. Latin America Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 93. Mexico Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 94. Mexico Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Brazil Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 96. Brazil Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Argentina Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 98. Argentina Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Latin America Cancer Immunotherapies Market Share by Type in 2019
Figure 100. Latin America Cancer Immunotherapies Market Share by Application in 2019
Figure 101. Middle East and Africa Cancer Immunotherapies Sales Growth Rate 2015-2020 (K Units)
Figure 102. Middle East and Africa Cancer Immunotherapies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 103. Middle East and Africa Cancer Immunotherapies Sales Market Share by Country in 2019
Figure 104. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Country in 2019
Figure 105. Turkey Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 106. Turkey Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Saudi Arabia Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 108. Saudi Arabia Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. U.A.E Cancer Immunotherapies Sales Growth Rate (2015-2020) (K Units)
Figure 110. U.A.E Cancer Immunotherapies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. Middle East and Africa Cancer Immunotherapies Market Share by Type in 2019
Figure 112. Middle East and Africa Cancer Immunotherapies Market Share by Application in 2019
Figure 113. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. ARMO BioSciences (Eli Lilly) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 122. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 123. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 124. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 125. North America Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 126. North America Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Europe Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 128. Europe Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Asia Pacific Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 130. Asia Pacific Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 131. Latin America Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 132. Latin America Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 133. Middle East and Africa Cancer Immunotherapies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 134. Middle East and Africa Cancer Immunotherapies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 135. Porter's Five Forces Analysis
Figure 136. Channels of Distribution
Figure 137. Distributors Profiles
Figure 138. Bottom-up and Top-down Approaches for This Report
Figure 139. Data Triangulation
Figure 140. Key Executives Interviewed
